Mareike Ostertag | Director Regulatory and Science Policy
Novartis Pharma AG

Mareike Ostertag, Director Regulatory and Science Policy, Novartis Pharma AG

Mareike Ostertag has extensive experience in the pharmaceutical industry. In over 16 years with Novartis, Dr. Ostertag held different roles with increasing responsibility within the company as well as with external industry- and non-industry partners. 
Roles included Technical Marketing, Global Project Management R&D, Alliance Management R&D as well as Public Private Partnership and Stakeholder Management for Middle East and Africa.
As part of her previous roles, she successfully led Due Diligence projects for Biologic development projects and was responsible for the integration and Alliance Management of licensed Biologics projects into the Novartis portfolio. 
In her current role, Mareike Ostertag focusses on policy issues related to R&D across the  Novartis Divisions, with specific focus on Biotherapeutics including Biosimilars, IP and R&D incentives and Orphan Diseases. 
Dr. Ostertag holds a degree in Veterinary Medicine from the University of Giessen, Germany and a PhD in cellular immunology. 
A native German, Mareike Ostertag has been living and working in Switzerland and the US throughout the past 12 years. She is married and today lives outside of Basel, Switzerland. 
Publication: Saunders (now Ostertag), M.; Taubert, A; Dafa’alla, T; Zahner, H: 
Effect of chemotherapeutic treatment on cytokine (IFN-γ, IL-2, IL-4, IL-5, IL-10) gene transcription in response to specific antigens in Brugia malayi-infected Mastomys coucha. Parasitol. Res. (2008) 103:1163-1176         


Biosimilars Day 2 - Wednesday 1st November 2017 @ 09:55

Panel Discussion on regulation and IP followed by questions from the audience

  • European Regulators positions on interchangeability and public study results as an introduction to the debate on how best to share and communicate real world evidence and pharmacovigilance data.
  • What are the most appropriate means and platforms which could reduce the gap between regulatory science and medical practice and which could inspire others to follow?

back to speakers